肿瘤蛋白激酶抑制剂致心衰的细胞靶点识别:药物警戒与药效动力学结合分析
研究利用VigiBase?对15种抗癌蛋白激酶抑制剂(PKI)进行病例/非病例分析,评估心衰(CF)风险并识别相关激酶靶点。达沙替尼、伊马替尼、博舒替尼、舒尼替尼和尼洛替尼的CF报告比值比显著升高;ABL1和ABL2激酶亲和力与aROR显著相关,提示ABL酪氨酸激酶在PKI致CF中起作用。
要点
- 达沙替尼、伊马替尼、博舒替尼、舒尼替尼和尼洛替尼的CF报告比值比显著高于其他PKI。
- ABL1(非磷酸化和磷酸化形式)和ABL2激酶亲和力与CF报告比值比显著相关。
- 临床使用上述PKI时应关注心衰风险,尤其达沙替尼aROR最高。
核心结论
- 达沙替尼、伊马替尼、博舒替尼、舒尼替尼和尼洛替尼的心衰报告比值比显著高于其他抗癌PKI。
- ABL酪氨酸激酶(ABL1非磷酸化/磷酸化形式及ABL2)与PKI所致心衰相关。
研究设计与样本
- 基于WHO VigiBase?的病例/非病例(case/noncase)分析,计算15种抗癌PKI的调整报告比值比(aROR)。
- 通过文献回顾识别21种可能参与PKI致心衰的蛋白激酶,计算aROR与PKI亲和力数据的Pearson相关系数。
主要发现
- 达沙替尼aROR为2.52(95%CI 2.26, 2.82),伊马替尼1.79(95%CI 1.57, 2.03),博舒替尼1.73(95%CI 1.18, 2.54),舒尼替尼1.67(95%CI 1.51, 1.84),尼洛替尼1.38(95%CI 1.18, 1.61)。
- ABL1非磷酸化形式r=0.83(P=0.0001),ABL1磷酸化形式r=0.75(P=0.0014),ABL2 r=0.78(P=0.0006)。
关键数值与推荐
- 达沙替尼aROR 2.52(95%CI 2.26, 2.82)显著高于其他PKI。
- 伊马替尼aROR 1.79(95%CI 1.57, 2.03)、博舒替尼1.73(95%CI 1.18, 2.54)、舒尼替尼1.67(95%CI 1.51, 1.84)、尼洛替尼1.38(95%CI 1.18, 1.61)心衰报告比值比显著升高。
- ABL1(非磷酸化和磷酸化形式)和ABL2亲和力与aROR相关系数分别为r=0.83(P=0.0001)、r=0.75(P=0.0014)、r=0.78(P=0.0006)。
临床怎么用
- 对使用达沙替尼、伊马替尼、博舒替尼、舒尼替尼或尼洛替尼的患者,应加强心衰监测与评估。
- ABL激酶抑制活性可能是PKI致心衰的机制线索,有助于优化药物选择与随访策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aims of the present study were to evaluate the risk of cardiac failure (CF) associated with 15 anticancer protein kinase inhibitors (PKIs) through a case/noncase analysis and to identify which PK(s) and pathways are involved in PKI-induced CF. METHODS: In order to evaluate the risk of CF, adjusted reporting odds ratios (aRORs) were calculated for the 15 anticancer PKIs in the World Health Organization safety report database (VigiBase®). We realised a literature review to identify 21 protein kinases (PKs) that were possibly involved in CF caused by PKIs. Pearson correlation coefficients (r) between aRORs and affinity data of the 15 PKIs for the 21 PKs were calculated to identify the cellular target most likely to be involved in PKI-induced CF. RESULTS: A total of 141 601 individual case safety reports (ICSRs) were extracted from VigiBase® for the following PKIs: afatinib, axitinib, bosutinib, crizotinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, ruxolitinib, sorafenib, sunitinib and vandetanib. Among them, 2594 ICSRs concerned CF. The disproportionality analysis revealed that, for dasatinib, imatinib, bosutinib, sunitinib and nilotinib, disproportionality for CF was significantly higher than for other PKIs, with aRORs of 2.52 [95% CI 2.26, 2.82], 1.79 (95% CI 1.57, 2.03), 1.73 (95% CI 1.18, 2.54), 1.67 (95% CI 1.51, 1.84) and 1.38 (95% CI 1.18, 1.61), respectively. Significant values for correlation coefficients between the product of dissociation constant (pKd) and aROR were observed for two non-receptor protein kinases: ABL1 (non-phosphorylated and phosphorylated forms) and ABL2 protein kinases, with values of r = 0.83 (P = 0.0001), r = 0.75 (P = 0.0014) and r = 0.78 (P = 0.0006), respectively. CONCLUSION: We observed a higher disproportionality for CF with dasatinib, imatinib, bosutinib, sunitinib and nilotinib than with other PKIs. In addition, the study highlighted the role of ABL tyrosine kinases in CF caused by anticancer PKIs.
引用
- Patras de Campaigno E, Bondon-Guitton E, Laurent G, et al. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics. Br J Clin Pharmacol. 2017. PMID: 28098949. doi:10.1111/bcp.13238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。